TY - JOUR
KW - extended‐release injectable naltrexone
KW - opioid use disorder
KW - Drug Therapy
KW - Substance use disorder
KW - Opiates
KW - Naltrexone
KW - Substance use treatment
KW - article
KW - 3383:Drug & Alcohol Rehabilitation
AU - Brantley P. Jarvis
AU - August F. Holtyn
AU - Shrinidhi Subramaniam
AU - D. A. Tompkins
AU - Emmanuel A. Oga
AU - George Bigelow
AU - Kenneth Silverman
A1 - 
AD - Johns Hopkins University School of Medicine, Baltimore, MD, US brantley.p.jarvis.ctr@mail.mil; Department of Psychology and Child Development, California State University, Stanislaus, Turlock, CA, US ; Department of Psychiatry, University of California San Francisco School of Medicine, Ringgold Standard Institution, San Francisco, CA, US ; Center for Applied Public Health Research, RTI International, Rockville, MD, US ; Jarvis, Brantley P.,brantley.p.jarvis.ctr@mail.mil
BT - Addiction
C5 - Opioids & Substance Use
CP - 1
DO - 10.1111/add.14462
IS - 1
JF - Addiction
LA - English
M1 - Journal Article
PB - Wiley-Blackwell Publishing Ltd. Blackwell Publishing
PY - 2019
SN - 0965-2140, 0965-2140
SP - 189
EP - 190
EP - 
T1 - Extended‐release injectable naltrexone (XR-NTX): A response to clinical issues raised by Brewer & Streel
T2 - Addiction
TI - Extended‐release injectable naltrexone (XR-NTX): A response to clinical issues raised by Brewer & Streel
U1 - Opioids & Substance Use
U3 - 10.1111/add.14462
VL - 114
VO - 0965-2140, 0965-2140
Y1 - 2019
Y2 - 01
ER -